Curevac B.V. Stock Price, News & Analysis

CureVac N.V. (NASDAQ:CVAC) announced the sale of 103,775 common shares by CEO Franz-Werner Haas, CFO Pierre Kemula, and Interim CDO Ulrike Gnad-Vogt. The sales were conducted solely to meet tax and social security liabilities from a legacy Virtual Stock Option Plan. Management clarified that they do not plan any additional share sales in the near future. Established in Tübingen, Germany, CureVac specializes in mRNA technology and has over 20 years of experience in developing therapeutic solutions.

CureVac (Nasdaq: CVAC) reported third-quarter 2022 revenues of €11.2 million, down 62% year-over-year, primarily due to the terminated collaboration with Boehringer Ingelheim. The company continues to progress its second-generation mRNA vaccine candidates in collaboration with GSK, with four Phase 1 trials underway and results expected in Q1 2023. Operating losses decreased to €52.4 million, while cash reserves stood at €540.9 million. CureVac plans to broaden its oncology initiatives with two proof-of-principle studies set to start in 2023, aiming to enhance its mRNA technology applications in cancer treatment.

CureVac N.V. (Nasdaq: CVAC) announced preliminary findings from the Phase 1 expansion study of CV8102, its oncology candidate. The data confirm the treatment's safety and its capability to activate the immune system against tumors. In a cohort of 30 patients treated with CV8102 and anti-PD-1 antibodies, 17% experienced partial responses lasting up to a year. No responses were seen in the single-agent cohort of 10 patients. Final Phase 1 data are expected in H1 2023, which will be published in a peer-reviewed journal.

CureVac N.V. (NASDAQ:CVAC) will report third quarter and first nine months 2022 financial results on November 16, 2022. A conference call will occur at 3 p.m. CET / 9 a.m. ET, allowing investors and stakeholders access to important business updates. CureVac is focused on developing mRNA-based therapies and is engaged in collaborations for vaccines against infectious diseases, including COVID-19. The company's technology aims to instruct the body to produce proteins that combat various diseases. More details are available on their website.

CureVac N.V. (Nasdaq: CVAC) reported its Q2 2022 financial results, revealing revenues of €20.1 million, a 10% decline year-over-year. Cash reserves stood at €573.6 million, down from €811.5 million as of December 2021. The company initiated Phase 1 trials for its modified COVID-19 vaccine candidate CV0501 targeting the Omicron variant and for the modified influenza vaccine FLU SV mRNA, developed in partnership with GSK. Additionally, CureVac acquired Frame Cancer Therapeutics to bolster its oncology strategy.

CureVac has initiated a Phase 1 clinical study for its modified COVID-19 mRNA vaccine candidate, CV0501, which targets the Omicron variant. This study aims to evaluate the safety and immunogenicity of CV0501 as a booster for previously vaccinated individuals. Conducted across clinical sites in the U.S., UK, Australia, and the Philippines, it plans to enroll up to 180 participants. This milestone underscores CureVac's commitment to advancing its second-generation vaccine technology in collaboration with GSK.

CureVac N.V. (Nasdaq:CVAC) announced that all proposals were approved during its annual general meeting, including the re-appointments and appointments of key supervisory and managing board members. Notable appointments include Craig Tooman, Dr. Debra Barker, and Dr. Klaus Schollmeier as supervisory board members, and Dr. Franz-Werner Haas and Dr. Malte Greune as managing directors. A detailed table of the voting results is expected soon. CureVac specializes in mRNA technology and collaborates with GSK on vaccine development.

CureVac N.V. (NASDAQ: CVAC) has acquired Frame Cancer Therapeutics for €32 million to enhance its oncology strategy. This acquisition will leverage Frame's advanced bioinformatics platform to identify unique neoantigens, potentially leading to innovative cancer vaccines. The acquisition involves a 50% upfront payment in CureVac shares, with additional payments tied to project milestones. The combined expertise is expected to accelerate the development of personalized and off-the-shelf cancer vaccines, strengthening CureVac's position in the oncology market.

CureVac N.V. (NASDAQ:CVAC) announced the appointment of Myriam Mendila as Chief Development Officer, effective February 1, 2023, succeeding Klaus Edvardsen, who will leave the company on June 30, 2022. Mendila brings over 20 years of experience in product development and oncology. Until her start date, Ulrike Gnad-Vogt will serve as interim CDO. CureVac expresses gratitude towards Edvardsen for his contributions, particularly in expanding their pipeline. The company continues to focus on advancing its mRNA technology for various medical applications.